[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@masonat7 "@PersimmonTI You think $AMGN would pay $5B+ for $NAMS after they originally sold off obicetrapib to NAMS for much less"
X Link @masonat7 2025-10-13T18:37Z XX followers, 4826 engagements

"$NAMS reminder that obicetrapib is not like other CETP inhibitors. Every other CETPi increased hs-CRP. Obicetrapib appears to modestly decrease hs-CRP"
X Link @masonat7 2025-10-13T16:45Z XX followers, XXX engagements

"@SnupSnus @PCM_bio @PersimmonTI There's going to be a big push to treat lp(a) if/when these lp(a) drugs get approved but insurance might only cover for 150nmol (similar to trial population) even though risk starts to increase at 50nmol. $NAMS is studying combo with repatha on lp(a) in the 50-150 range"
X Link @masonat7 2025-10-14T20:55Z XX followers, XXX engagements